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Influenza Preparedness: Avian, Pandemic
On January 6, 2007, a 22-year-old female from Lagos, 
Nigeria, died of what is suspected to be a case of avian 
influenza. The mother of the 22-year-old died on January 
4, 2007, with similar symptoms. Preliminary tests on the 
samples from the 22-year-old were positive for influenza 
type A (H5N). 
One of CDC’s most important roles is to protect the 
nation’s health from emerging health threats, such as the 
threat of an influenza pandemic. While a pandemic has not 
yet occurred, it is important that the United  States and the 
world remain vigilant and be ready to respond. 
The circulation of avian influenza type A (H5N) virus 
in domestic and wild birds is expected to continue. As a 
result, people with exposure to sick or dead birds remain at 
risk of being infected with H5N virus. In addition, as long 
as the virus continues to circulate, there is the possibility 
that it will undergo genetic changes that allow it to be 
easily transmitted from person-to-person.
To help prepare for a possible pandemic, CDC is 
carefully monitoring changes in the virus that might 
allow it to evolve into a strain that could result in a 
pandemic. CDC collaborates across the U.S. government 
under the leadership of the State Department and with 
global partners such as WHO and national ministries of 
health. This collaboration has proved to be an effective 
partnership and is playing an important role in the early 
identification of suspected cases of avian flu in Nigeria. 
Some key CDC activities in Africa include these:
Assisting the investigation of the H5N outbreak in 
poultry, in Nigeria (February 2006)
Training for influenza surveillance and laboratory 
testing in Uganda 
Rapid Response Team training in Kenya for English-
speaking countries of Africa
Dispatching an EIS Officer from the Influenza Division 
to Nigeria in August 2006 to help the country develop 
a plan for avian influenza and seasonal influenza 
surveillance
Dispatching epidemiologists from the Global Disease 
Detection center in Kenya to investigate the recent 
human cases in Nigeria
Fortunately, there is no evidence of efficient human-to-
human transmission. CDC is also monitoring mutations in 
the H5N virus that could  result in resistance to antiviral 
medications.  For example, in January 2007 an Egyptian 
H5N virus indicated a small change in susceptibility to the 
antiretroviral medication oseltamivir. However, there is no 
widespread indication of resistance in Egypt or globally.
While monitoring the virus is critical, it is only 
half the battle. Emergency management and 
preparedness planning are among CDC’s most pressing 
responsibilities—both domestically and internationally.  
While CDC continues to improve preparedness within 
U.S. borders, CDC also assists other countries to develop 
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detect and respond to new influenza viruses, and to 
identify and contain a pandemic at its earliest stage.  For 
optimal response, an emerging influenza pandemic 
outbreak anywhere in the world must be recognized 
within 72 hours, investigated, and then confirmed within 
days. A successful response will require an unprecedented 
and well-coordinated containment effort involving dozens 
of trained teams, broadly disseminated public health 
messages, social-isolation and movement-restriction 
considerations, and the treatment of patients and 
potential contacts. 
Experts from CDC’s Influenza Division and Global 
Disease Detection (GDD) Centers are strengthening the 
agency’s resources on the ground by improving current 
surveillance systems, training and equipping rapid-
response teams in high-priority countries, supporting 
the expansion of the WHO Influenza Network, assisting 
countries with investigation of and response to outbreaks, 
and facilitating the availability of needed protective 
equipment and supplies for first responders to a potential 
pandemic.  Much of the capacity that is being developed 
by CDC and its partners extends beyond the threat posed 
by avian influenza to help regions and countries to prepare 
for other emerging threats as well. 
Rift Valley Fever
At the request of the Kenya Ministry of Health, the Centers 
for Disease Control and Prevention (CDC) within the 
U.S. Department of Health and Human Services (HHS) 
is working closely with Kenyan health and veterinary 
officials in response to an outbreak of Rift Valley Fever 
(RVF) in Northeastern Kenya. As of January 25, 2007, the 
Kenyan Ministry of Health had reported 404 human cases 
(2 laboratory confirmed) and 5 deaths related to the 
outbreak. 
A viral disease, RVF causes sudden fever and, more 
rarely, serious complications including hemorrhagic fever, 
encephalitis, and blindness. While RVF primarily affects 
livestock, such as sheep and cattle, humans who are 
bitten by infected mosquitoes or other insects are also 
susceptible. Rift Valley Fever is generally found in regions 
of eastern and southern Africa. The United States has 
never experienced an outbreak of Rift Valley Fever, but 
the virus—like the West Nile virus—could reach the U.S., 
posing a threat to both human and animal health. 
The Centers for Disease Control and Prevention (CDC) 
within the U.S. Department of Health and Human Services 
(HHS) is leading the U.S. Government’s response to the 
outbreak.  Other members of the USG team are the U.S. 
Army Medical Research Unit-Kenya, the Animal and Plant 
Health Inspection Service within the U.S. Department of 
Agriculture, and Naval Medical Research Unit-3. The World 
Health Organization (WHO) and its partners from the 
Global Outbreak Alert and Response Network (GOARN) are 
also actively engaged in the investigation and efforts to 
contain the outbreak. 
CDC is helping Kenya’s Ministry of Health  to enhance 
its surveillance and response strategies, to revise standard 
case definitions to help accurately identify cases of 
suspected infections, to identify risk factors for disease 
transmission, and to craft health communications and 
media messages. CDC is also assisting the Ministry of 
Livestock and Fisheries Development with training 
and capacity building of veterinary labs, including the 
transfer of technology, and working with the Department 
of Veterinary Services within the Ministry of Livestock 
to improve their data management systems. Similar 
assistance has been provided in Tanzania.
In recent weeks, 8 experts from CDC’s Global Disease 
Detection (GDD) Center in Kenya and from the CDC’s 
offices in Atlanta, Georgia, and Ft. Collins, Colorado have 
helped investigate the outbreak in Nairobi and affected 
provinces.  Also collaborating on the investigation are the 
current trainees and graduates of the Kenya CDC Field 
Epidemiology and Laboratory Training Program (FELTP) 
and representatives from the CDC-supported Kenya 
Medical Research Institute (KEMRI). KEMRI and the Kenya 
GDD Center have also provided laboratory support to 
confirm diagnosed cases. The improved detection of new 
cases and knowledge of how the virus is being spread will 
enable a swifter and more targeted response. 
CDC continues to play a strong role in identifying the 
source and patterns of transmission of Rift Valley in order 
to effectively control the current outbreak of RFV. This 
information will play an important role in the development 
of prevention and intervention strategies for Rift Valley 
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Fever in endemic countries to limit the public health threat 
posed by RVF.  For more information on the Rift Valley 
fever outbreak, please visit www.cdc.gov/mmwr/preview/
mmwrhtml/mm5604a3.htm?s_cid=mm5604a3_e . 
XDR TB: Old Foe Poses New Threat
CDC is actively engaged in addressing the emerging 
global concern stemming from reports of extensively 
drug-resistant tuberculosis (XDR TB), first described in the 
March 24, 2006 issue of the Morbidity and Mortality Weekly 
Report (MMWR).  XDR TB is defined as M. tuberculosis strains 
which meet the definition for multidrug-resistant TB (MDR 
TB) with additional resistance to fluoroquinolones and at 
least one of the second-line injectable drugs (amikacin, 
kanamycin, or capreomycin).  The loss of these additional 
drugs leaves most patients virtually untreatable with 
currently available drugs.  
Based on a joint CDC-WHO survey of 4 supranational 
reference labs, this MMWR provided an alert that XDR TB 
has emerged worldwide as a threat to public health and TB 
control.
The report documented the occurrence of XDR TB in 
47 countries on six continents, including the United States. 
U.S. patients with XDR TB are 64% more likely to die during 
treatment than patients with multidrug-resistant (MDR) 
TB.   Additionally, reports from a province in South Africa 
describe a recent outbreak of XDR TB in an HIV-infected 
population, characterized by alarmingly high death 
rates. Of 536 patients with TB, 22 (4.2%) had multi-
drug resistant (MDR) TB and, of these, 53 had extensive 
drug-resistant (XDR) TB. Nearly all (98%) of the individuals 
with XDR TB died—/2 of them within 6 days and 70% 
within one month.  Forty-four of these persons were 
tested for HIV; all were positive and had been receiving 
antiretroviral drugs.  These data likely represent the “tip 
of the iceberg” of highly drug-resistant TB predominantly 
affecting HIV-infected individuals in that country and 
other regions of the world. The harrowing implication 
of these highly resistant strains of TB spreading among 
clients accessing HIV care and treatment services, such as 
those spearheaded by the President’s Emergency Plan for 
AIDS Relief (PEPFAR), has necessitated concerted and swift 
responses. 
CDC, in collaboration with WHO and the South Africa 
Medical Research Council (MRC), convened an Expert 
Consultation on Drug Resistant TB in the African Region 
in Johannesburg in September 2006.  CDC demonstrated 
expertise in rapid response, surveillance, building 
laboratory capacity and infection control helped inform 
discussion at this meeting. 
On-going activities supported by PEPFAR have also 
been accelerated in the context of overall TB program 
strengthening as the critical element to prevent drug-
resistance.  Staff 
from CDC work 
with their PEPFAR-
implementing 
colleagues in other 
U.S. Government 
Agencies and those 





mobilize financial and 
technical resources to respond to XDR TB.
The U.S. Government has convened a U.S. Federal 
TB Task Force to discuss a domestic and international 
response plan for U.S. Government agencies on XDR-
TB.  The White House is also planning to convene an 
interagency meeting in the next few weeks to ensure 
a unified strategic approach. The U.S. Government also 
participates in the WHO Global XDR-TB Task Force which is 
finalizing a global plan to respond to XDR-TB.   
Mystery Illness in Panama Solved
On October 2, 2006, the Gorgas Memorial Institute of 
Health Research (GMIHR) in Panama City asked the Centers 
for Disease Control and Prevention (CDC) to join the 
Ministry of Health and Pan American Health Organization 
(PAHO) for assistance in tracking down an unknown 
killer.  A mysterious illness, producing acute renal failure 
and weakness in adults, had appeared in 2 seriously ill 
patients in the Latin American nation, leading to death in 
more than half of them.
A team with expertise in epidemiology, medical 
toxicology, neurology and infectious disease was 
assembled by CDC Atlanta as well as staff from CDC’s 
regional office in Guatemala. The team hit the ground 
running in Panama, quickly distributing supplies and 
equipment to gather medical data and diagnostic 
samples from patients—as well as gathering samples 
from suspected sources of the possible poisoning—and 
returning them to Atlanta’s laboratories. The rapid 
delivery of supplies to Panama and return transportation 
of diagnostic samples for testing by CDC and FDA was 
facilitated through use of CDC’s leased airplane. 
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CDC and United States Food and Drug Administration 
(FDA) laboratories conducted several comprehensive and 
exhaustive analyses for a wide variety of both chemical 
and infectious agents in biologic specimens as well as 
reviewed kidney and nerve tissue specimens for evidence 
of infectious diseases.  CDC and FDA laboratories also 
collaborated to assess the purity of various medications 
associated with case-patients and conducted targeted 
testing for specific agents in these medications suspected 
of causing this illness. In just nine days, CDC scientists 
working with numerous international partners were able 
to identify the cause of this disease.
Diethylene glycol (DEG) somehow was introduced into 
several locally produced medications including a sugarless 
cough syrup. DEG is a water-soluble, clear liquid commonly 
found in brake fluids, antifreeze, and fuel additives that can 
cause potent kidney and nervous system damage when 
ingested by humans.
Once the contaminant was identified, Panamanian 
health authorities quickly withdrew the contaminated 
medications from clinics, and began a national public 
health prevention and risk communication program. 
They notified people through the media as well as 
through door-to-door visits to not use these products. 
Thanks to this remarkable scientific detective work, it 
is likely that many lives were saved. CDC will translate 
lessons learned during this experience to prevent further 
poisonings. 
Measles Initiative Surpasses Goal
Measles deaths have fallen by 60% worldwide, from an 
estimated 873,000 deaths in 999 to 345,000 in 2005—a 
major public health success. This exceeds the United 
Nation’s goal to halve measles deaths by 2005, and is 
largely due to an unprecedented decline in measles deaths 
in the African region. 
In Africa, measles deaths fell by 75%, from an estimated 
506,000 to 26,000. This announcement was made on 
January 8, 2007, by partners in the Measles Initiative: the 
American Red Cross, CDC, the United Nations Foundation, 
UNICEF, and the World Health Organization. The data was 
published in the January 20 edition of the Lancet. The 75% 
reduction in measles deaths in Africa is due to the firm 
commitment and resources of national governments and 
support from the Measles Initiative.
A four-component strategy has been the key to 
ensuring the massive global decrease in measles deaths. 
The strategy calls for
The provision of one dose of measles vaccine for all 
infants, via routine health services
A second opportunity for measles immunization 
for all children, generally through mass vaccination 
campaigns
Effective surveillance for measles
Enhanced care, including provision of supplemental 
Vitamin A





global measles immunization coverage with the first 
routine dose increased from 7% to 77%, and more than 
360 million children aged 9 months to 5 years received 
measles vaccine through immunization campaigns.
In addition, measles vaccination campaigns are 
contributing to the reduction of child deaths from other 
causes. They have become a channel for the delivery of 
other life-saving interventions, such as
Bed nets to protect against malaria
De-worming medicine
Vitamin A supplements
In 2006 alone, an estimated 8 million bed nets were 
provided to families in nine African countries during 
Measles Initiative-supported campaigns.  Combining 
measles immunization with other health interventions 
is a contribution to the achievement of the Millennium 
Development Goal to reach a two thirds reduction in child 
deaths between 999 and 205. There is still some way to 
go in the fight against one of the world’s most contagious 
diseases. Of the estimated 345,000 measles deaths in 2005, 
90% were among children under the age of 5—many 
dying as a result of complications related to severe 
diarrhea, pneumonia, and encephalitis.
CDC’s Global Immunization Division (GID) contributes 
funds and technical assistance to partner activities in 
priority countries around the world. GID’s technical 
assistance supports the implementation of high-quality 
measles campaigns to strengthen field and laboratory 
surveillance for measles virus detection and for efforts 
to strengthen national routine immunization systems in 
priority countries. 
Since 200, CDC has contributed more than $50 
million for the purchase of bundled measles vaccine 
(more than 280 million doses) to the UN Foundation. 
This contribution has generated matching funds of more 
than $6 million in support of measles surveillance and 
routine immunizations helping to sustain the gains made 
through this innovative partnership on reducing measles 
mortality and morbidity in priority countries supported by 





agency’s ability to respond to public health threats, and its 
ability to expand the focus of a public health intervention 
strategically to prevent other emergent public health 
threats. 
President’s Malaria Initiative: A  
Call for Action
The global toll of malaria is high: an estimated one million 
people die each year, most of them young children in 
Africa. Malaria’s impact extends beyond the infected 
individual. It also weakens economies by leaving adults 
too sick to work for days each year and requiring large 
expenditures by ministries of health and families. Malaria-
related illness and mortality are estimated to cost Africa’s 
economy $2 billion per year. 
In June 2005 President Bush announced the $.2 
billion President’s Malaria Initiative (PMI) with the goal to 
cut malaria deaths in half in targeted African countries.   
PMI assists national governments in delivering a 
comprehensive package of proven, effective interventions 
to a majority (85%) of people at greatest risk—pregnant 
women and children less than 5 years old. 
From PMI’s inception, CDC has worked closely with 
USAID to design the initiative. CDC has helped conceive 
and lead implementation of the plan for evaluating PMI’s 
impact in achieving its goal. In support of PMI activities, 
CDC provides assistance with implementation of scale 
up activities and leadership in formulating strategies and 
conducting activities to monitor and evaluate program 
outcomes and impacts. USAID and CDC work with host 
Ministries of Health, other U.S. agencies (National Institutes 
of Health, U.S. Department of State); the Global Fund to 
Fight AIDS, TB, and Malaria; the World Bank; Roll Back 
Malaria; U.N. Children’s Foundation (UNICEF); and other 
organizations to achieve the President’s goal. 
Within 6 months of the President’s announcement, 
work was under way in the first 3 (fiscal year 2006) 
countries targeted: Angola, Tanzania, and Uganda. In 
November 2006, PMI began work in the next 4 (fiscal year 
2007) targeted countries—Malawi, Mozambique, Rwanda, 
and Senegal. 
The final 8 countries targeted for the initiative 
were named at the White House Summit on Malaria, 
December 4, 2006–Benin, Ethiopia, Ghana, Kenya, Liberia, 
Madagascar, Mali, and Zambia. Activities in these countries 
are scheduled to begin in fiscal year 2008. To date, PMI has 
provided life-saving interventions to more than 6 million 
people. 
